Date: 2017-05-24
Type of information: Product acquisition
Compound: immunotherapies targeting immune checkpoints
Company: Pierre Fabre laboratories (France) Igenica Biotherapeutics (USA - CA)
Therapeutic area: Cancer - Oncology
Type agreement: product acquisition
Action mechanism: immunotherapy product/immune checkpoint inhibitor
Disease:
Details:
- • On May 24, 2017, Pierre Fabre Laboratories announced
the signature of a definitive purchase agreement to acquire several assets from Igenica Biotherapeutics, based in Burlingame, California, USA. The agreement includes innovative immunotherapies targeting immune checkpoints that may reverse the resistance to existing immuno therapies. The most advanced asset is currently at preclinical stage and is expected to be administered to patients in the coming 2 to 3 years. The agreement also comprises a series of early discovery targets.
- Under the terms of the agreement, Pierre Fabre has acquired the full property of the assets.
Financial terms: The financial terms of the agreement are not disclosed.
Latest news:
Is general: Yes
